Childhood brain tumors : diagnosis and therapy - comprehensive genomic profiling
With the advancement of molecular oncology, numerous new opportunities are available for the effective and efficient treatment of patients diagnosed with childhood brain tumors. This includes gene panel analysis aiding personalized treatment used in clinical trials, and the application of targeted therapy independent of tissue type (tumor agnostic therapy). Most personalized therapies inhibit certain kinases. In our review, we present the modern pathological diagnosis of childhood brain tumors, as well as the complex intracellular regulation of signal transduction pathways important from the point of view of clinical practice, and we describe their further targets defined on the basis of pharmacological characteristics of the pathway, based on international and our own results. Despite common mutations affecting kinases, personalized therapy is not available in many types of tumors. Through the example of childhood brain tumors, we demonstrate the expected future therapeutic significance of tyrosine kinases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
Magyar onkologia - 67(2023), 4 vom: 18. Dez., Seite 315-320 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Gyermekkori agydaganatok: diagnózis és terápia – komprehenzív genomikai profilozás |
|---|
| Beteiligte Personen: |
Brückner, Edit [VerfasserIn] |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 20.12.2023 Date Revised 20.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM366002139 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366002139 | ||
| 003 | DE-627 | ||
| 005 | 20231227134936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||hun c | ||
| 028 | 5 | 2 | |a pubmed24n1233.xml |
| 035 | |a (DE-627)NLM366002139 | ||
| 035 | |a (NLM)38109510 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Brückner, Edit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Childhood brain tumors |b diagnosis and therapy - comprehensive genomic profiling |
| 246 | 3 | 3 | |a Gyermekkori agydaganatok: diagnózis és terápia – komprehenzív genomikai profilozás |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2023 | ||
| 500 | |a Date Revised 20.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a With the advancement of molecular oncology, numerous new opportunities are available for the effective and efficient treatment of patients diagnosed with childhood brain tumors. This includes gene panel analysis aiding personalized treatment used in clinical trials, and the application of targeted therapy independent of tissue type (tumor agnostic therapy). Most personalized therapies inhibit certain kinases. In our review, we present the modern pathological diagnosis of childhood brain tumors, as well as the complex intracellular regulation of signal transduction pathways important from the point of view of clinical practice, and we describe their further targets defined on the basis of pharmacological characteristics of the pathway, based on international and our own results. Despite common mutations affecting kinases, personalized therapy is not available in many types of tumors. Through the example of childhood brain tumors, we demonstrate the expected future therapeutic significance of tyrosine kinases | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Bedics, Gábor |e verfasserin |4 aut | |
| 700 | 1 | |a Reiniger, Lilla |e verfasserin |4 aut | |
| 700 | 1 | |a Rajnai, Hajnalka |e verfasserin |4 aut | |
| 700 | 1 | |a Jakab, Zsuzsanna |e verfasserin |4 aut | |
| 700 | 1 | |a Bödör, Csaba |e verfasserin |4 aut | |
| 700 | 1 | |a Scheich, Bálint |e verfasserin |4 aut | |
| 700 | 1 | |a Garami, Miklós |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Magyar onkologia |d 1961 |g 67(2023), 4 vom: 18. Dez., Seite 315-320 |w (DE-627)NLM092654185 |x 2060-0399 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2023 |g number:4 |g day:18 |g month:12 |g pages:315-320 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2023 |e 4 |b 18 |c 12 |h 315-320 | ||